(Total Views: 402)
Posted On: 06/10/2020 8:55:09 AM
Post# of 36566
Item 8.01 Other Events.
On April 28, 2020, Generex Biotechnology Corporation (“Generex”) received a letter of support from 3M Company (“3M”) regarding Generex’s efforts to develop Generex’s li- Key-SARS-CoV-2 peptide vaccine with the goal to begin mass vaccination in the Fall of 2020. A copy of the letter of support is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
About 3M; 3M applies science in collaborative ways to improve lives daily. With $32 billion in sales, its 96,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com.
Forward-Looking Statements
On April 28, 2020, Generex Biotechnology Corporation (“Generex”) received a letter of support from 3M Company (“3M”) regarding Generex’s efforts to develop Generex’s li- Key-SARS-CoV-2 peptide vaccine with the goal to begin mass vaccination in the Fall of 2020. A copy of the letter of support is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
About 3M; 3M applies science in collaborative ways to improve lives daily. With $32 billion in sales, its 96,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com.
Forward-Looking Statements
(1)
(0)
